- Home
- INMD vs GHRS Comparison
INMD vs GHRS Comparison
Compare INMD & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMD
- GHRS
- Stock Information
- Founded
- INMD 2008
- GHRS 2018
- Country
- INMD Israel
- GHRS Ireland
- Employees
- INMD N/A
- GHRS N/A
- Industry
- INMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- INMD Health Care
- GHRS Health Care
- Exchange
- INMD Nasdaq
- GHRS Nasdaq
- Market Cap
- INMD 964.9M
- GHRS 774.1M
- IPO Year
- INMD 2019
- GHRS 2021
- Fundamental
- Price
- INMD $14.53
- GHRS $13.59
- Analyst Decision
- INMD Hold
- GHRS Strong Buy
- Analyst Count
- INMD 6
- GHRS 9
- Target Price
- INMD $17.06
- GHRS $29.33
- AVG Volume (30 Days)
- INMD 774.5K
- GHRS 311.3K
- Earning Date
- INMD 11-05-2025
- GHRS 11-07-2025
- Dividend Yield
- INMD N/A
- GHRS N/A
- EPS Growth
- INMD 20.42
- GHRS N/A
- EPS
- INMD 2.21
- GHRS N/A
- Revenue
- INMD $364,494,000.00
- GHRS N/A
- Revenue This Year
- INMD N/A
- GHRS N/A
- Revenue Next Year
- INMD $5.02
- GHRS N/A
- P/E Ratio
- INMD $6.57
- GHRS N/A
- Revenue Growth
- INMD N/A
- GHRS N/A
- 52 Week Low
- INMD $13.14
- GHRS $6.72
- 52 Week High
- INMD $19.85
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- INMD 40.07
- GHRS 50.43
- Support Level
- INMD $14.48
- GHRS $12.50
- Resistance Level
- INMD $15.86
- GHRS $14.77
- Average True Range (ATR)
- INMD 0.41
- GHRS 0.95
- MACD
- INMD -0.13
- GHRS -0.00
- Stochastic Oscillator
- INMD 20.74
- GHRS 50.21
About INMD InMode Ltd.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.